Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of hematological malignancy, including any of the following:
• •* Chronic myeloid leukemia
• •* Acute myeloid leukemia
• •* Acute lymphocytic leukemia
• •* Myelodysplastic syndromes
• •* Lymphoma
• •Unlikely to respond to conventional treatment and would benefit from hematopoietic stem cell transplantation
• •No bulky tumor mass requiring additional involved field radiotherapy
• •No large body burden of tumor cells requiring cytoreductive chemotherapy before total body irraditation and cyclophosphamide
• •Undergoing conditioning for transplantation at the University of Washington Medical Center
• •Availability of 1 of the following types of allogeneic donors:
• •* HLA-identical family members
• •* Unrelated donors
• •* Allele match (match grade 1)
• •* One allele mismatch for A, B, C, DRB1 or DQB1 (match grades 2.1 or 2.2)
• •PATIENT CHARACTERISTICS:
• •Age
• •18 to 65
• •Performance status
• •Not specified
• •Life expectancy
• •Not severely limited by diseases other than malignancy
• •Not moribund
• •Hematopoietic
• •Not specified
• •Hepatic
• •Bilirubin no greater than 1.2 mg/dL
• •No cirrhosis
• •No hepatic fibrosis with bridging
• •Renal
• •Creatinine no greater than 1.2 mg/dL
• •Cardiovascular
• •No coronary artery disease
• •No congestive heart failure requiring therapy
• •Pulmonary
• •Oxygen saturation at least 93% (on room air)
• •Other
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •HIV negative
• •No concurrent infection requiring systemic antibiotic or antifungal therapy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior hematopoietic stem cell transplantation
• •Chemotherapy
• •See Disease Characteristics
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •See Disease Characteristics
• •No prior radiotherapy to the liver or adjacent organs
• •Surgery
• •Not specified
• •Other
• •No concurrent aspirin or nonsteroidal anti-inflammatory medications such as ibuprofen (e.g., Motrin® or Advil®)
• •No other concurrent phase I study enrollment